If you're exploring medical weight loss options in 2026, two names dominate the conversation: semaglutide (sold as Ozempic and Wegovy) and tirzepatide (sold as Mounjaro and Zepbound). Both are weekly injectable medications that have revolutionized obesity medicine, but they work differently — and the clinical trial data suggests meaningful differences in how much weight patients lose.
This guide breaks down the science, the trial data, the side effects, and the practical considerations to help you and your provider decide which medication may be the better fit.
The Mechanism: GLP-1 Only vs. GLP-1 + GIP Dual Agonist
Understanding how these drugs differ starts at the molecular level.
Semaglutide: GLP-1 Receptor Agonist
Semaglutide mimics glucagon-like peptide-1 (GLP-1), a hormone released by intestinal L-cells after eating. By activating GLP-1 receptors, semaglutide:
- Stimulates glucose-dependent insulin secretion from the pancreas
- Suppresses glucagon (preventing inappropriate glucose release)
- Slows gastric emptying (creating prolonged fullness)
- Acts on hypothalamic receptors to reduce appetite and food reward
Tirzepatide: GLP-1 + GIP Dual Receptor Agonist
Tirzepatide is a first-in-class dual incretin receptor agonist. In addition to activating GLP-1 receptors, it also activates glucose-dependent insulinotropic polypeptide (GIP) receptors. GIP is the other major incretin hormone — released by intestinal K-cells — and it plays distinct roles:
- Amplifies insulin secretion in a glucose-dependent manner
- Reduces glucagon secretion (complementing GLP-1's effect)
- Appears to act on adipose (fat) tissue to enhance fat metabolism and reduce fat storage
- May reduce the nausea associated with pure GLP-1 agonism by modulating GLP-1 receptor sensitivity
The dual mechanism gives tirzepatide additional metabolic levers — particularly through GIP's action on fat cells — that may explain its superior weight loss outcomes in clinical trials.
Clinical Trial Data: SURMOUNT vs. STEP
The most important comparison comes from two landmark trial programs:
STEP Trials (Semaglutide)
The STEP (Semaglutide Treatment Effect in People with Obesity) trials evaluated semaglutide 2.4 mg weekly (Wegovy) in adults with obesity over 68 weeks. Key findings:
- STEP 1: Mean weight loss of 14.9% of body weight vs. 2.4% with placebo
- STEP 4: Participants who switched to placebo regained most of their weight, confirming treatment must be maintained
- 68% of participants achieved ≥10% weight loss
- 32% achieved ≥20% weight loss
SURMOUNT Trials (Tirzepatide)
The SURMOUNT program evaluated tirzepatide at 5 mg, 10 mg, and 15 mg weekly doses over 72 weeks. Key findings:
- SURMOUNT-1: Mean weight loss of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) vs. 3.1% with placebo
- At the highest dose (15 mg), 57% of participants lost ≥20% of body weight
- Average absolute weight loss at 15 mg: approximately 52 lbs for those starting at 230 lbs
Direct Head-to-Head: The SURMOUNT-5 Trial
In 2024, the SURMOUNT-5 trial provided the first direct head-to-head comparison of tirzepatide (max 15 mg) vs. semaglutide (max 2.4 mg) in adults with obesity but without diabetes. Results:
- Tirzepatide: 20.2% mean weight loss
- Semaglutide: 13.7% mean weight loss
- Tirzepatide demonstrated approximately 47% greater weight loss relative to semaglutide
This is not a trivial difference. For a 250-pound person, that's roughly 50 lbs with tirzepatide vs. 34 lbs with semaglutide — a 16-pound advantage that could be clinically meaningful for many patients.
Side Effect Profile Comparison
Both medications share similar side effect profiles, given their overlapping GLP-1 mechanism:
| Side Effect | Semaglutide 2.4 mg | Tirzepatide 15 mg |
|---|---|---|
| Nausea | ~44% | ~33% |
| Diarrhea | ~30% | ~23% |
| Vomiting | ~24% | ~13% |
| Constipation | ~24% | ~17% |
| Discontinuation due to GI AEs | ~4.5% | ~4.3% |
Interestingly, tirzepatide appears to have a somewhat milder GI side effect profile despite its greater efficacy — a counterintuitive finding that researchers hypothesize may relate to GIP receptor activation modulating GLP-1 receptor-mediated nausea signaling. Both drugs carry the same black box warning regarding medullary thyroid carcinoma and are contraindicated in patients with MEN2 or MTC history.
Cost Comparison in 2026
Cost remains a significant practical consideration:
- Wegovy (semaglutide 2.4 mg): ~$1,300–$1,500/month list price; with insurance coverage or manufacturer coupons, out-of-pocket may be $0–$500/month for eligible patients
- Zepbound (tirzepatide): ~$1,050–$1,300/month list price; Eli Lilly's self-pay program has offered vials as low as $349–$499/month
- Compounded semaglutide: $200–$400/month via compounding pharmacies (currently in a gray zone following FDA shortage status resolution)
- Compounded tirzepatide: $200–$450/month via compounding pharmacies (availability varies by state and regulatory environment)
Insurance coverage for obesity medications remains inconsistent. Medicare Part D covers Zepbound but not Wegovy for weight loss. Many commercial plans have added coverage for both, particularly after employer plan expansions. Your Truventa provider can help navigate prior authorization and assistance programs.
Who May Be a Better Candidate for Each Medication?
Semaglutide May Be Preferred When:
- You have insurance that covers Wegovy but not Zepbound (or vice versa)
- You've had a good response to semaglutide previously
- Your provider recommends starting with a single-agonist approach
- You're using compounded semaglutide for cost reasons and have good availability
- You have type 2 diabetes and Ozempic is covered for glycemic management
Tirzepatide May Be Preferred When:
- Maximum weight loss is the priority and you qualify medically
- You tried semaglutide with inadequate results (less than 5% weight loss at optimal dose)
- You have insulin resistance or metabolic syndrome (tirzepatide's GIP action may provide additional metabolic benefits)
- You want potentially better GI tolerability while achieving superior efficacy
- Zepbound's self-pay vial program makes it cost-competitive for your situation
Compounded Versions: What You Need to Know
During the height of the GLP-1 shortage, compounded versions of both semaglutide and tirzepatide became widely prescribed. The regulatory landscape has evolved significantly:
- FDA removed both semaglutide and tirzepatide from its drug shortage list in 2024/2025, which triggered limits on compounding by 503B outsourcing facilities
- 503A compounding pharmacies (which compound for individual prescriptions) may still compound these drugs with appropriate clinical justification
- Quality, potency, and sterility of compounded products vary — working with a licensed provider who uses vetted pharmacies is essential
At Truventa Medical, our providers discuss all FDA-approved and compounded options transparently, helping patients make informed decisions about their treatment path. Learn more about our tirzepatide program, Zepbound options, Wegovy program, and semaglutide treatment.
Switching Between Medications
Some patients start with one medication and switch to the other. This is clinically reasonable and well-documented:
- Inadequate response to semaglutide: Patients who achieve less than 5% weight loss after 16 weeks on optimal semaglutide dosing are often better served by switching to tirzepatide
- Side effect intolerance: If semaglutide causes persistent intolerance, tirzepatide's somewhat different GI profile may be better tolerated (though there are no guarantees)
- Formulary changes: Insurance coverage shifts may necessitate switching for cost reasons
When switching, providers typically manage the transition by timing the new medication to begin after the last dose of the prior medication, with careful dose titration from the starting dose of the new drug.
Both Drugs Require Long-Term Use
One of the most important findings from the clinical trials is that weight regain is substantial when either medication is discontinued. This is because GLP-1 drugs address a hormonal environment that promotes weight regain — they don't cure the underlying biology. When the medication stops, hunger hormones normalize and weight often returns within 12–18 months.
This isn't a failure — it's the nature of obesity as a chronic disease. Just as hypertension medication needs to be continued to maintain blood pressure control, GLP-1 therapy typically needs to be maintained for sustained benefit. Your provider should discuss a long-term management strategy before you begin either medication.
The Bottom Line
Based on the available trial data, tirzepatide achieves greater weight loss than semaglutide — approximately 20% vs. 14% of body weight at maximum approved doses, with a 47% relative advantage demonstrated in the head-to-head SURMOUNT-5 trial. It also appears to have a somewhat milder GI side effect profile despite its superior efficacy.
However, semaglutide remains an excellent medication with robust evidence supporting meaningful, sustained weight loss for the majority of patients. Insurance coverage, cost, availability, individual response, and your overall metabolic picture all play a role in choosing the right medication for you.
The best choice is the one made in partnership with a knowledgeable provider who understands your full health history and goals. Truventa Medical's licensed physicians across all 50 states are available to help you navigate this decision and build a personalized treatment plan.